SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending intensely following Saudi Arabia's groundbreaking approval of its Anktiva treatment for lung cancer, marking the first global nod for this non-chemo combination, alongside significant progress in its AI-driven NK cell manufacturing. This development, amplified by Dr. Patrick Soon-Shiong's direct public engagement, is fueling widespread community excitement about a potential paradigm shift in oncology and fervent speculation regarding a short squeeze amidst high market interest. Investors and patients alike are discussing the implications of international regulatory confidence and the company's efforts to revolutionize cancer treatment accessibility and cost, putting immense pressure on traditional pharmaceutical and regulatory landscapes.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point due to its imminent earnings report and ongoing speculation regarding its potential acquisition of Warner Bros. Discovery assets. The community is sharply divided, debating the strategic implications of the WBD deal and reacting to news of a notable bond purchase by a prominent political figure. Traders are anticipating significant volatility, with many viewing the stock as oversold and poised for a substantial move.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amidst an "unprecedented" memory shortage, fueled by surging AI demand for High-Bandwidth Memory (HBM) that experts project will persist into 2027. The community is highly optimistic, highlighting Micron's unique position as the sole U.S. HBM producer, its relatively low valuation, and recent analyst upgrades. This strong bullish sentiment is reinforced by news of significant manufacturing expansions and a substantial insider share purchase.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is currently trending due to a sharp price drop and heightened volatility, fueled by recent critical reports and ongoing speculation of market manipulation. Despite the downturn, community discussions highlight conviction in its robust AI-powered ad platform and anticipate a rebound, particularly with upcoming earnings expected to showcase strong fundamentals.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept Inc. (VERO) is trending following the disclosure that a single institutional shareholder now controls 91% of the company's shares, creating an extremely tight public float. This has spurred a heated debate among investors, with many anticipating an unprecedented short squeeze and significant price appreciation due to the limited tradable shares. Conversely, a vocal group warns of a potential pump-and-dump, highlighting the company's underlying fundamentals and the risk of delisting at a low valuation.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively discussed amidst renewed concerns over potential US tariffs on European economies related to Greenland, which has prompted caution in European markets and the bond sector. This geopolitical tension has sharply divided the community, with many anticipating a significant market pullback, while a strong counter-narrative expects a swift "buy the dip" recovery based on historical resilience to similar events.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors anticipate an upcoming business update call, which follows a major joint venture with a Saudi industrial conglomerate securing 100% offtake for its Greenland rare earth production. The community is buzzing with discussion around Greenland's strategic importance for critical minerals, intensified by geopolitical developments highlighting the need for secure supply chains. This confluence of news positions CRML as a central focus for those seeking exposure to the crucial rare earths sector.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively trending due to reports of China blocking shipments of its H200 AI chips, coupled with broader market uncertainty from escalating international trade tensions. While some investors anticipate market turbulence, a strong bullish contingent emphasizes NVIDIA's entrenched AI leadership and robust demand for its next-generation Blackwell and Rubin platforms, viewing current dips as prime buying opportunities.

PDD Holdings, Inc. is a multinational commerce group that owns and operates a portfolio of businesses. The company aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from increased productivity and new opportunities. It has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses. PDD Holdings was founded by Hua Lin Cai and Zheng Huang in 2015 and is headquartered in Dublin, Ireland.

PDD Holdings Inc - ADR

Pinduoduo Inc.

PDD is trending due to a deepening regulatory probe in China, reportedly involving physical altercations with regulators, which led Morgan Stanley to remove it as a top pick. This has split community opinion, with some fearing escalating risks and challenges for its global Temu business, while others highlight strong fundamentals and see a significant buying opportunity amidst the dip.

Smith & Wesson Brands, Inc. is a holding company, which engages in the manufacture, design, and provision of firearms. Its portfolio includes handguns, long guns, handcuffs, suppressor, and other firearm-related products. The firm's brands are Smith & Wesson, M&P, Thompson/Center Arms, and Gemtech. The company was founded by Horace Smith and Daniel Baird Wesson in 1852 and is headquartered in Maryville, TN.

Smith & Wesson Brands Inc

Smith & Wesson Brands is trending due to a mix of recent disappointing earnings and significant regulatory developments. While the company missed profit and revenue estimates, sparking community concerns, there's a strong undercurrent of optimism driven by proposed Justice Department changes to ease gun regulations and the rescission of strict firearm export controls. Investors are actively discussing the potential for increased firearm demand amid broader themes of civil unrest and political uncertainty, positioning the stock as a long-term play despite short-term headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Protagenic Therapeutics, Inc. (PTIX) jumped 244% on Monday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=6&amp;b=2612&amp;ID=145678&amp;m=rl&amp;g=1834">announced</a> its merger with private pharmaceutical firm Phytanix Bio Inc.Protagenic said the two companies have entered into a definitive share exchange agreement, under which they will combine in an all-stock transaction.The combined entity will be called Phytanix, Inc., and will bring together the two companies’ pipelines focused on stress-related and central nervous system (CNS) disorders. While Protagenic makes peptides for stress-related disorders, Phytanix Bio specializes in developing medicines manufactured from cannabinoids and "cannabinoid-like" molecules.The combined entity will have five preclinical assets and one clinical-stage asset, Protagenic added.Protagenic executive chairman Garo H. Armen noted that the combination aligns two pipelines with complementary assets and expertise to develop drugs in neuropsychiatry, CNS, and other disorders.Protagenic said that post-combination, pre-financing ownership will be approximately 35% for the company's pre-combination stockholders and approximately 65% for Phytanix Bio stockholders on a fully diluted basis.Protagenic had announced a 1-for-14 reverse stock split of its issued and outstanding common stock earlier this month to bring the company into compliance with the minimum bid price requirement for continued listing on Nasdaq.On Stocktwits, retail sentiment around Protagenic jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_19_at_10_28_13_AM_png_a07fae3fc6.webp" alt="PTIX's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 19, 2025 | Source: Stocktwits" width="628" height="65"><figcaption>PTIX's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user believes the stock could rally further toward $15.<stembedurl>https://stocktwits.com/cjstocksup/message/615100995</stembedurl><a href="https://stocktwits.com/symbol/PTIX">PTIX stock</a> gained over 43% this year but is down by about 48% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/netflix-stock-edges-lower-after-jp-morgan-downgrade-despite-higher-price-target/ch0cubqRb82">Netflix Stock Edges Lower After JPMorgan Downgrade Despite Higher Price Target</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish

The new entity will be called Phytanix, Inc., and it will combine the two companies’ pipelines focused on stress-related and CNS disorders.

Equity

Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Current Price	$0.59
Prev Close	$0.54
Open	$0.63
Dividend Yield	0.00%
50-Day Moving Average	$1.57
Beta	-0.49
Avg. Volume	0.00
PE Ratio	-0.08

52-Week High	$4.35
52-Week Low	$0.2601
Market Capitalization	$1.14M
EPS (Annual)	-$15.79
Price to Book	-0.24
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PTIX
Protagenic Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PTIX News

PTIXProtagenic Therapeutics Inc